Skip to content
Search

Latest Stories

MHRA warns of 'potential risk' associated with NSAIDs in last trimester of pregnancy

Medicines and Healthcare products Regulatory Agency (MHRA) has reminded healthcare professionals that use of systemic (oral and injectable) Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, and diclofenac is contraindicated in the last trimester of pregnancy (after 28 weeks of pregnancy).

It has advised that patients who are unsure whether pain relief medicine they are taking is an anti-inflammatory (NSAID), to speak to doctor, midwife, or pharmacist.


Some non-prescription pain relief medicines may contain more than one active drug, therefore it is important to read the box or the leaflet provided with the medicine to see if it contains an NSAID like ibuprofen.

The use of any non-prescription medicine for the management of pain during pregnancy should be for the shortest possible time at the lowest possible dose, suggested MHRA.

A review of data from a 2022 study has identified that prolonged use of NSAIDs from week 20 of pregnancy onwards may be associated with an increased risk of oligohydramnios (low levels of amniotic fluid surrounding the baby) and fetal renal dysfunction.

Some cases of constriction of the ductus arteriosus (narrowing of a connecting blood vessel in the baby’s heart) have also been identified at this early stage.

MHRA suggested : "If, following consultation between the patient and a healthcare professional, use of a systemic NSAID after week 20 of pregnancy is considered necessary, it should be prescribed for the lowest dose for the shortest time and additional neonatal monitoring considered if used for longer than several days."

More For You

NHS pharmacy funding not enough 2025: £3.073B deal with £1.99B gap fuels reform debate.

Funding alone isn’t going to be enough to save community pharmacy

Photo credit: gettyimages

New funding contract ‘not enough’ to release the sector from financial blackhole

After almost a year without an agreement, a new funding contract for community pharmacy was finally announced yesterday (31 March).

The settlement raises the baseline annual funding for the Community Pharmacy Contractual Framework (CPCF) in 2025/26 to £3.073 billion, with an additional £215 million secured to continue Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Pharmacy First: Government confirms £215 million boost to realise its full potential

From April 2025, the consultation fee for Pharmacy First Minor Illness and Clinical Pathways will rise from £15 to £17.

‘Pharmacy First hasn't realised its full potential,’ says Stephen Kinnock

Health Minister Stephen Kinnock has acknowledged that Pharmacy First has huge potential, noting that the service “hasn't realised its full potential.”

As part of efforts to enhance the service, Kinnock yesterday (30) announced £215 million in additional funding for Pharmacy First and other Primary Care Access Recovery Plan services.

Keep ReadingShow less
Free morning-after pill at pharmacies to end postcode lottery for patients

Pharmacy technicians will be allowed to supply of drospirenone for contraception under PGD,

gettyimages

Pharmacy contract: Free morning-after pill to be available at pharmacies soon

The UK government has announced that, for the first time ever, the ‘morning-after pill’ or emergency contraceptive pill will be available free of charge at pharmacies on the NHS, ending the postcode lottery women face in accessing the medicine and reducing inequalities.

The Department of Health and Social Care (DHSC) has confirmed a record £3.073 billion funding package for community pharmacies in 2025/26, alongside an additional £215 million to sustain Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Royal College status: The PDA calls for ‘meaningful and collaborative dialogue’

The profession’s success will depend on collaboration across all sectors, says PDA.

gettyimages

Royal College vote: Less than 7% of GB pharmacists in favour, says PDA

The Pharmacists’ Defence Association (PDA) has criticised the Royal Pharmaceutical Society (RPS) for moving too quickly to a ballot on its proposed transition to a Royal College, arguing that it resulted in low participation from pharmacists in Great Britain.

Announcing the results of the special resolution vote, the RPS said that the outcome was a “clear mandate” in favour of the transformative change.

Keep ReadingShow less
RPS Wales calls for urgent investment in pharmacy workforce at Senedd meeting

Third from the left: Eluned Morgan, First Minister of Wales

Photo credit: RPS

Invest in pharmacy workforce: RPS Wales urges Senedd members

Members of the Senedd (MSs) were briefed on the increasing pressures facing pharmacy teams and the urgent need for action to support their health and wellbeing at an event hosted by the Royal Pharmaceutical Society (RPS) Wales.

The event, held on Wednesday, brought together MSs, including first minister Eluned Morgan, to discuss the findings of RPS’ latest Workforce Wellbeing Survey.

Keep ReadingShow less